Blood cytokine response of low-dose molgramostim (rhGM-CSF)-treated patients

Thomas Hartung, Sonja Von Aulock, Marcus Freitag, Stefan Höxtermann, Markus Stücker, Klaus Hoffmann, Peter Altmeyer, Andrea Kottke, Albrecht Wendel

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


We examined leukocyte counts and ex vivo cytokine response of whole blood to lipopolysaccharide (LPS) or lipoteichoic acid (LTA) in patients under low-dose molgramostim therapy. Patients were injected subcutaneously daily for ten days with 1 μg/kg (n =9) or 2 μg/kg (n = 14) molgramostim. Leukocytosis was observed in all patients, but only the eosinophil fraction was significantly increased in relation to other leukocyte populations. Ex vivo IFN-γ release was decreased and IL-10 and IL-1ra secretion were increased in response to LPS or LTA. Thus, in non-neutropenic patients, leukocytosis can already be initiated by Bow doses of molgramostim. The ex vivo cytokine data suggest that these doses prime blood towards a systemic anti-inflammatory response. (C) 2000 Academic Press.

Original languageEnglish (US)
Pages (from-to)1570-1574
Number of pages5
Issue number10
StatePublished - 2000
Externally publishedYes


  • Blood
  • Cytokines
  • Growth factors
  • Human
  • Inflammation

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Biochemistry
  • Hematology
  • Molecular Biology


Dive into the research topics of 'Blood cytokine response of low-dose molgramostim (rhGM-CSF)-treated patients'. Together they form a unique fingerprint.

Cite this